Alecensa FDA Approval History
FDA Approved: Yes (First approved December 11, 2015)
Brand name: Alecensa
Generic name: alectinib
Dosage form: Capsules
Company: Genentech, Inc.
Treatment for: Non-Small Cell Lung Cancer
Alecensa (alectinib) is an oral, anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).
Development timeline for Alecensa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.